Wedbush Comments on TScan Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Stock analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for shares of TScan Therapeutics in a note issued to investors on Wednesday, April 17th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($0.26) for the quarter. Wedbush has a “Outperform” rating and a $10.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.04) per share. Wedbush also issued estimates for TScan Therapeutics’ Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.28) EPS and Q4 2025 earnings at ($0.27) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. The business had revenue of $7.21 million for the quarter, compared to the consensus estimate of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%.

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 7th.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX opened at $6.75 on Thursday. TScan Therapeutics has a 12-month low of $1.62 and a 12-month high of $9.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.51 and a quick ratio of 6.51. The stock’s 50 day simple moving average is $7.02 and its 200 day simple moving average is $5.63.

Institutional Trading of TScan Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in TScan Therapeutics by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 1,788,152 shares of the company’s stock valued at $10,425,000 after acquiring an additional 35,558 shares during the period. BlackRock Inc. increased its position in TScan Therapeutics by 1.4% in the 1st quarter. BlackRock Inc. now owns 1,519,188 shares of the company’s stock valued at $4,254,000 after acquiring an additional 20,650 shares during the period. abrdn plc acquired a new stake in TScan Therapeutics in the 4th quarter valued at approximately $1,166,000. Renaissance Technologies LLC increased its position in TScan Therapeutics by 1,171.2% in the 2nd quarter. Renaissance Technologies LLC now owns 147,462 shares of the company’s stock valued at $369,000 after acquiring an additional 135,862 shares during the period. Finally, Woodline Partners LP increased its position in shares of TScan Therapeutics by 37.1% during the 1st quarter. Woodline Partners LP now owns 136,930 shares of the company’s stock valued at $383,000 after purchasing an additional 37,030 shares during the period. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.